Leri's pleonosteosis, a congenital rheumatic disease, results from microduplication at 8q22.1 encompassing GDF6 and SDC2 and provides insight into systemic sclerosis pathogenesis. Read more about Leri's pleonosteosis, a congenital rheumatic disease, results from microduplication at 8q22.1 encompassing GDF6 and SDC2 and provides insight into systemic sclerosis pathogenesis.
A Chemical Tool for In Vitro and In Vivo Precipitation of Lysine Methyltransferase G9a. Read more about A Chemical Tool for In Vitro and In Vivo Precipitation of Lysine Methyltransferase G9a.
New strategies to inhibit KEAP1 and the Cul3-based E3 ubiquitin ligases. Read more about New strategies to inhibit KEAP1 and the Cul3-based E3 ubiquitin ligases.
Structures of soluble guanylate cyclase: implications for regulatory mechanisms and drug development. Read more about Structures of soluble guanylate cyclase: implications for regulatory mechanisms and drug development.
Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition. Read more about Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition.
The Structural Basis of PI3K Cancer Mutations: From Mechanism to Therapy. Read more about The Structural Basis of PI3K Cancer Mutations: From Mechanism to Therapy.
The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface. Read more about The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.
Structural characterization of a new N-substituted pantothenamide bound to pantothenate kinases from Klebsiella pneumonia and Staphylococcus aureus. Read more about Structural characterization of a new N-substituted pantothenamide bound to pantothenate kinases from Klebsiella pneumonia and Staphylococcus aureus.
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Read more about EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor. Read more about Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor.
